Recent Company News

• 06:22 PM ET Jul 07, 2025
  

  FDA approves Cochlear's Nucleus Nexa System, Nucleus Kanso 3 and Kanso 3 Nexa Sound Processors (A$300.74, 0.00)

• 12:10 AM ET Jun 25, 2025
  

  StreetAccount Scorecard - Australian ASX200 short interest as at 19-Jun

• 05:06 PM ET Jun 17, 2025
  

  Cochlear upgraded to buy from neutral at UBS (A$281.66, 0.00)

• 09:51 PM ET Apr 10, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 08:41 PM ET Jun 12, 2025
  

  Street Takeaways - Cochlear downgrades FY guidance (A$272.31, 0.00)

• 09:41 PM ET Jun 11, 2025
  

  Cochlear opens (8.4%), currently (0.8%) on downgraded FY NPAT guidance below consensus expectations (A$268.29, -2.17)

• 06:28 PM ET Jun 11, 2025
  

  Cochlear guides FY underlying NPAT A$390-400M vs prior guidance to lower end of A$410-430M and FactSet A$411.5M [10 est, A$406.8-414.9M] (A$270.46, 0.00)

• 06:55 PM ET Apr 08, 2025
  

  StreetAccount Market Summary - Impact of US tariffs in Australia

• 07:51 PM ET Apr 07, 2025
  

  Cochlear will continue to rely on the Harmonized Tariff Schedule that provides duty-free importation into the US, includes hearing implants (A$253.33, 0.00)